The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content


Nuvo Pharmaceuticals Inc closed at $6.37.

Over the last five days, shares have gained 6.17% and 22.26% year to date. Shares have outperformed the S&P TSX by 55.74% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward5.99×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$0.65
Updated May 4 3:58 PM EDT. Delayed by at least 15 minutes.

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Fiscal Quarter Endvalues in $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Total other revenue--------
Total revenue8635
Gross profit5312
Total cost of revenue3323
Total operating expense8795
Selling / general / administrative3331
Research & development2242
Depreciation / amortization0000
Interest expense (income), net operating0000
Unusual expense (income)00----
Other operating expenses, total--------
Operating income0-2-6-1
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets0------
Income before tax0-1-60
Income after tax0-1-60
Income tax, total0000
Net income0-1-60
Total adjustments to net income--------
Net income before extra. items0-1-60
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items0-1-60
Inc. avail. to common incl. extra. items0-1-60
Diluted net income0-1-60
Dilution adjustment--------
Diluted weighted average shares11111111
Diluted EPS excluding extraordinary itemsvalue per share0.03-0.11-0.55-0.02
Dividends per sharevalue per share--
Diluted normalized EPSvalue per share0.03-0.11-0.55-0.02